SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This approval strengthens Dupixent's dominance in type 2 inflammation markets and supports future U.S. approval prospects. Traders should monitor the FDA decision on the sBLA for pediatric CSU, which could further expand commercial reach. Despite recent insider selling, the clinical and regulatory momentum supports continued premium valuation.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$745.61
T+0 close · Apr 13, 2026 · via day close
Latest settled
−9.30%
T+60 · $676.23
Vs SPY
−18.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $745.61entry
  2. T+1 · 7mo ago +1.29%α +0.08% · $755.25
  3. T+5 · 7mo ago +0.49%α −2.81% · $749.26
  4. T+20 · 6mo ago −4.81%α −12.54% · $709.73
  5. T+60 · 4mo ago −9.30%α −18.28% · $676.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU), expanding its label to younger patients. This marks the first targeted therapy for this age group in the EU and strengthens Dupixent's position in type 2 inflammation-driven diseases.

Key Facts

  • European Commission approved Dupixent for children 2 to 11 years with CSU who are unresponsive to antihistamines and naïve to anti-IgE therapy.
  • Approval based on LIBERTY-CUPID trial program, including extrapolated adult efficacy data and pediatric safety/efficacy from CUPIDKids trial.
  • Dupixent is now approved for children under 12 across four chronic type 2 inflammatory diseases.
  • U.S. supplemental Biologics License Application (sBLA) for this population is under review.

Financial Impact

Expands Dupixent's eligible patient population in the EU, increasing long-term revenue potential; no immediate revenue figure provided but represents a meaningful lifecycle extension.

revenuemarket shareproduct lifecycle

Risk Factors

  • Regulatory delays or restrictions in other geographies for this indication.
  • Competition from biosimilars or alternative therapies in development.
  • Safety profile could evolve with broader pediatric use.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272191

Track record

53 reports on REGN

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026